# US 2022/0031676 A1 · Methods of treating disease with magl inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031676 A1
- Document ID: US20220031676A1
- Status: Published application
- Kind: A1
- Application number: 17/296,489
- Filed: 2019-11-26
- Published: 2022-02-03
- Earliest claimed: 2018-11-28
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Channing Rodney BEALS; Dallas JONES; Jason Robert CLAPPER; Gary Paul O'NEILL; Iain Peter FRASER; Jacqueline Lorayne BLANKMAN; John J.M. WIENER; Cheryl A. GRICE
- Web page: https://patentgrep.com/patent/US20220031676A1

## CPC

- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for the treatment of disease with monoacylglycerol lipase (MAGL) inhibitors.

## Claims

### Claim 1

A method for treating a disease or a condition in a patient wherein the disease or condition is selected from atopic dermatitis, bladder dysfunction associated with multiple sclerosis, cardiovascular disease, contact dermatitis, cystic fibrosis, dermatomyositis, eczema, endometriosis, enteritis, fibromyalgia, Tourette syndrome, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, ischemia, labor, abdominal pain, abdominal pain associated with irritable bowel syndrome, acute pain, back pain, cancer pain, chest pain, functional chest pain, joint pain, menstrual pain, metabolic disorders, musculoskeletal diseases, neuropathy, osteoarthritis, pancreatitis, pharyngitis, post mastectomy pain syndrome, post trigeminal neuralgia, post operative pain, renal ischemia, rheumatoid arthritis, skeletal muscle contusion, skin diseases, sunburn, systemic lupus erythematosus, toothache, vasoocclusive painful crises in sickle cell disease, and visceral pain, comprising administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I) having the structure:
wherein:
R1 is —C(O)OR15 or —C(O)NR10R11;
R2 is H, halogen, C1-6alkyl, or C1-6haloalkyl;
R3 is
A is N or C(H);
X is —O—, —N(R16)—, or —CH2N(R16)CH2—;
Y is —CH2— or —C(O)—;
Z is —S—, —O—, or —N(R18)—;
R4 is H, halogen, —OR7, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, —C(O)NR8R9, C3-8cycloalkyl, C2-9heterocycloalkyl, —C1-6alkyl-C2-9heterocycloalkyl, C6-10aryl, or C1-9heteroaryl, wherein C3-8cycloalkyl, C2-9heterocycloalkyl, —C1-6alkyl-C2-9 heterocycloalkyl, C6-10aryl, or C1-9heteroaryl are optionally substituted with 1 or 2 R14;
R5 is H, halogen, C1-6alkyl, C1-6haloalkyl, C1-6haloalkoxy, or phenyl;
R6 is H, halogen or C1-6alkyl;
R7 is H, C1-6alkyl, C1-6haloalkyl, —C1-6alkyl-OH, C2-9heterocycloalkyl, C6-10aryl, or C1-9heteroaryl, wherein C2-9heterocycloalkyl, C6-10aryl, or C1-9heteroaryl are optionally substituted with 1 or 2 R14;
each R8 and each R9 are independently selected from H and C1-6alkyl; or R8 and R9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;
R10 and R11 are each independently H or C1-6alkyl;
R12 is H, halogen, or C1-6alkyl;
R13 is H or C1-6alkyl;
each R14 is independently selected from halogen, —OH, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, —C1-6alkyl-OH, C3-8cycloalkyl, —C(O)OH, —C(O)NR8R9, —SO2—C1-6alkyl, and —N(R17)C(O)—C1-6alkyl;
R15 is H or C1-6alkyl;
R16 is H, C1-6alkyl, —C(O)—C1-6alkyl, —C1-6alkyl-OH, or —CH2CO2H;
R17 is H or C1-6alkyl;
R18 is H or C1-6alkyl;
v is 0 or 1;
n is 0 or 1;
m is 0 or 1;
p is 0, 1, or 2; and
q is 0, 1 or 2;
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R is

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, q is 0, and p is 2.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Y is —CH2— and A is C(H).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R12 is H and R13 is H.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R4 is halogen, —OR7, C1-6haloalkyl, C2-9heterocycloalkyl, C6-10aryl, or C1-9heteroaryl, wherein C2-9 heterocycloalkyl, C6-10aryl, or C1-9heteroaryl are optionally substituted with 1 or 2 R14.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R4 is halogen or R4 is C2-9heterocycloalkyl optionally substituted with 1 or 2 R14.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R2 is H, R6 is H, and R5 is H, halogen, C1-6alkyl, C1-6haloalkyl, or C1-6haloalkoxy.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R1 is —C(O)OR15 and R15 is H.

### Claim 10 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The method of claim 1, or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the compound is
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is selected from:
or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.
